These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12437503)

  • 1. A Rho-kinase inhibitor, soluble guanylate cyclase activator and nitric oxide-releasing PDE5 inhibitor: novel approaches to erectile dysfunction.
    Cellek S; Rees RW; Kalsi J
    Expert Opin Investig Drugs; 2002 Nov; 11(11):1563-73. PubMed ID: 12437503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
    Bi Y; Stoy P; Adam L; He B; Krupinski J; Normandin D; Pongrac R; Seliger L; Watson A; Macor JE
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1577-80. PubMed ID: 15006407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunction.
    Pissarnitski DA; Asberom T; Boyle CD; Chackalamannil S; Chintala M; Clader JW; Greenlee WJ; Hu Y; Kurowski S; Myers J; Palamanda J; Stamford AW; Vemulapalli S; Wang Y; Wang P; Wu P; Xu R
    Bioorg Med Chem Lett; 2004 Mar; 14(5):1291-4. PubMed ID: 14980684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of action of PDE5 inhibition in erectile dysfunction.
    Corbin JD
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S4-7. PubMed ID: 15224127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current oral treatments for erectile dysfunction.
    Kalsi JS; Cellek S; Muneer A; Kell PD; Ralph DJ; Minhas S
    Expert Opin Pharmacother; 2002 Nov; 3(11):1613-29. PubMed ID: 12437495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JNJ-10280205 and JNJ-10287069: Novel PDE5 inhibitors as clinical candidates for erectile dysfunction.
    Qiu Y; Bhattacharjee S; Kraft P; Mathew John T; Haynes-Johnson D; Jiang W; Sui Z; Lundeen S
    Int J Impot Res; 2006; 18(5):477-83. PubMed ID: 16528290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapy of erectile dysfunction in 2005].
    Porst H
    Urologe A; 2003 Oct; 42(10):1330-6. PubMed ID: 14569381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat.
    de Tejada IS
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S40-2. PubMed ID: 15224136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimisation of PDE5 inhibitor therapy in men with erectile dysfunction: converting "non-responders" into "responders".
    Eardley I
    Eur Urol; 2006 Jul; 50(1):31-3. PubMed ID: 16517052
    [No Abstract]   [Full Text] [Related]  

  • 10. Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction.
    Aversa A; Bruzziches R; Pili M; Spera G
    Curr Pharm Des; 2006; 12(27):3467-84. PubMed ID: 17017940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model.
    De Young L; Yu D; Freeman D; Brock GB
    Int J Impot Res; 2003 Oct; 15(5):347-54. PubMed ID: 14562136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations.
    Rosen RC; Shaw JW
    Int J Impot Res; 2006; 18(6):570-1; author reply 572-3. PubMed ID: 17075585
    [No Abstract]   [Full Text] [Related]  

  • 13. NCX-911, a novel nitric oxide-releasing PDE5 inhibitor relaxes rabbit corpus cavernosum in the absence of endogenous nitric oxide.
    Kalsi JS; Kell PD; Cellek S; Ralph DJ
    Int J Impot Res; 2004 Apr; 16(2):195-200. PubMed ID: 14961060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
    Rotella DP; Sun Z; Zhu Y; Krupinski J; Pongrac R; Seliger L; Normandin D; Macor JE
    J Med Chem; 2000 Apr; 43(7):1257-63. PubMed ID: 10753463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitric oxide regulation of penile erection: biology and therapeutic implications.
    Burnett AL
    J Androl; 2002; 23(5):S20-6. PubMed ID: 12236169
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardiovascular data on sildenafil citrate: introduction.
    Zusman RM
    Am J Cardiol; 1999 Mar; 83(5A):1C-2C. PubMed ID: 10078536
    [No Abstract]   [Full Text] [Related]  

  • 17. Sildenafil (Viagra) evokes retinal arteriolar dilation: dual pathways via NOS activation and phosphodiesterase inhibition.
    Yuan Z; Hein TW; Rosa RH; Kuo L
    Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):720-5. PubMed ID: 18235020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of phosphodiesterase 5 inhibition in erectile dysfunction.
    Rosen RC; Kostis JB
    Am J Cardiol; 2003 Nov; 92(9A):9M-18M. PubMed ID: 14609619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postnatal maturation of phosphodiesterase 5 (PDE5) in piglet pulmonary arteries: activity, expression, effects of PDE5 inhibitors, and role of the nitric oxide/cyclic GMP pathway.
    Moreno L; Losada B; Cogolludo Al; Lodi F; Lugnier C; Villamor E; Moro M; Tamargo J; Pérez-Vizcaíno F
    Pediatr Res; 2004 Oct; 56(4):563-70. PubMed ID: 15295092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence and success of PDE5 inhibitors as effective therapy for erectile dysfunction.
    Manganiello V
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S1-3. PubMed ID: 15224126
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.